Cytotoxic T cell polyepitope vaccines delivered by ISCOMs.

[1]  A. Osterhaus,et al.  A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. , 2000, Vaccine.

[2]  J. Maguire,et al.  Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. , 2000, Vaccine.

[3]  A. Suhrbier,et al.  Effect of pre‐existing cytotoxic T lymphocytes on therapeutic vaccines , 2000, European journal of immunology.

[4]  S. Kent,et al.  Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity , 1999, Immunological reviews.

[5]  F. Lemonnier,et al.  An HLA-A2 polyepitope vaccine for melanoma immunotherapy. , 1999, Journal of immunology.

[6]  F. Ennis,et al.  Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). , 1999, Virology.

[7]  J. Gardner,et al.  Immunogenicity of a Human Immunodeficiency Virus (HIV) Polytope Vaccine Containing Multiple HLA A2 HIV CD8+ Cytotoxic T-Cell Epitopes , 1999, Journal of Virology.

[8]  A. Suhrbier,et al.  Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems. , 1999, Vaccine.

[9]  I. Barr,et al.  ISCOMs: an adjuvant with multiple functions , 1998, Journal of leukocyte biology.

[10]  J. Bates,et al.  Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines. , 1998, Vaccine.

[11]  D. Moss,et al.  Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. , 1998, Journal of immunology.

[12]  J. Altman,et al.  Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.

[13]  A. Sjölander,et al.  Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. , 1997, Cellular immunology.

[14]  X. Mo,et al.  Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. , 1996, Journal of immunology.

[15]  D J Moss,et al.  Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  C. Rice,et al.  CD8+ T cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope , 1992, The Journal of experimental medicine.

[17]  S. Jonjić,et al.  A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection , 1988, Journal of virology.

[18]  J. Schlom,et al.  Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  F. Lemonnier,et al.  Immunogenicity of an HIV polytope vaccine containing multiple HLA-A2 HIV CD8+ cytotoxic T cell epitopes , 1999 .